

The impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapy

Citation for published version (APA):

Ramaekers, B. L. T., Joore, M. A., Grutters, J. P. C., van den Ende, P., de Jong, J., Houben, R., Lambin, P., Christianen, M., Beetz, I., Pijls-Johannesma, M., & Langendijk, J. A. (2011). The impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapy. *Oral Oncology*, 47(8), 768-774. <https://doi.org/10.1016/j.oraloncology.2011.05.012>

Document status and date:

Published: 01/08/2011

DOI:

[10.1016/j.oraloncology.2011.05.012](https://doi.org/10.1016/j.oraloncology.2011.05.012)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:


www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.



The impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapy

Bram L.T. Ramaekers^{a,b,*}, Manuela A. Joore^{b,c}, Janneke P.C. Grutters^b, Piet van den Ende^a, Jos de Jong^a, Ruud Houben^a, Philippe Lambin^a, Miranda Christianen^d, Ivo Beetz^d, Madelon Pijls-Johannesma^{a,1}, Johannes A. Langendijk^{d,1}

^a Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands

^b Department of Health Organization, Policy and Economics (HOPE), Maastricht University, Maastricht, The Netherlands

^c Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, The Netherlands

^d Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

ARTICLE INFO

Article history:

Received 4 November 2010

Received in revised form 13 May 2011

Accepted 18 May 2011

Available online 17 June 2011

Keywords:

Quality of life

Head and neck cancer

Xerostomia

Dysphagia

Radiotherapy

SUMMARY

To examine the impact of late treatment-related xerostomia and dysphagia on health-related quality of life (HRQOL) in head and neck cancer (HNC) patients after radiotherapy. A multi-center cross-sectional survey was performed. Patients with a follow-up of at least 6 months after curative radiotherapy, without evidence of recurrent disease were eligible for inclusion. The Euroqol-5D questionnaire (EQ-5D) was filled out and toxicity was scored and converted to the RTOG scale. The EQ-5D measures generic HRQOL in terms of utility and visual analogue scale (VAS) scores. Missing data on the EQ-5D were imputed using multiple imputation. HRQOL was compared between subgroups of patients with and without toxicity. Subsequently, the impact of xerostomia and dysphagia on HRQOL was analyzed using multivariate regression analyses. Both analyses were performed separately for utility scores and VAS scores. The study population was composed of 396 HNC patients. The average utility and VAS scores were 0.85 (scale 0–1) and 75 (scale 0–100). Subgroups of patients with xerostomia and/or dysphagia showed statistically significantly lower utility and VAS scores ($P = 0.000–0.022$). The multivariate regression model showed that xerostomia and dysphagia were negative predictors of both utility and VAS scores. Other factors which influenced HRQOL in at least one of the two regression models were: sex, tumor location and the addition of surgery to radiotherapy. Xerostomia and dysphagia diminish generic HRQOL. Moreover dysphagia affects patients' HRQOL stronger than xerostomia.

© 2011 Elsevier Ltd. Open access under the [Elsevier OA license](http://www.elsevier.com/locate/elsevier).

Introduction

An increasing number of options become available for the treatment of head and neck cancer (HNC). Traditionally, treatment decisions were primarily based on local tumor control and the length of survival. However, treating HNC often involves a trade-off between

(disease-free) survival and treatment-related toxicity. After radiotherapy, in particular xerostomia and dysphagia negatively affect health-related quality of life (HRQOL).^{1,2} Therefore, the length of survival after treatment has to be weighed against the quality of survival. As a result, HRQOL and factors influencing HRQOL (such as treatment-related toxicity) are increasingly recognized as important treatment outcomes in HNC.^{1,3–5}

To take into account HRQOL, disease-specific measures are often used. Although these questionnaires are relevant for patients and physicians, the main disadvantage of disease-specific measures is their inability to compare HRQOL in different disease areas. In contrast, generic HRQOL can be compared in different disease areas. Measures of generic HRQOL assess the preferences of individuals for a certain health status; the more preferable the outcome, the higher the score.⁶ This can be measured by inquiring how patients value their own health status (patients' perspective) or based on the preferences of the society (general public perspective). Preferences for health states can be combined with life

* Corresponding author at: Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Developmental Biology, Maastricht University Medical Center, P.O. Box 616, 6200 MD Maastricht, The Netherlands. Tel.: +31 0 43 38 84 504; fax: +31 0 43 38 84 162.

E-mail addresses: b.ramaekers@maastrichtuniversity.nl (B.L.T. Ramaekers), m.joore@mumc.nl (M.A. Joore), j.grutters@maastrichtuniversity.nl (J.P.C. Grutters), piet.vandenende@maastro.nl (P. van den Ende), jos.dejong@maastro.nl (J.de Jong), ruud.houben@maastro.nl (R. Houben), philippe.lambin@maastro.nl (P. Lambin), m.e.m.c.christianen@rt.umcg.nl (M. Christianen), i.beetz@rt.umcg.nl (I. Beetz), madelon.pijls@maastro.nl (M. Pijls-Johannesma), j.a.langendijk@rt.umcg.nl (J.A. Langendijk).

¹ These authors contributed equally to this work.

expectancy, resulting in quality adjusted life years (QALYs). The main advantage of QALYs is that they capture life expectancy and quality of life in a single measure.⁶ This is useful to inform the aforementioned trade-off between length of survival and treatment-related toxicity (quality of survival).

Previous studies have assessed health state preferences in HNC.^{7–11} However, to our knowledge, no study provided health state preferences based on subgroups distinguished by treatment-related toxicity for primary treated HNC patients. Hence, knowledge on the impact of toxicity on generic HRQOL is lacking. Therefore, we aimed to examine the impact of late treatment-related xerostomia and dysphagia on HRQOL (patient and general public perspective) in disease free HNC patients treated with radiotherapy.

The aim of this study was twofold: (1) to compare HRQOL across subgroups subdivided by xerostomia and dysphagia and (2) to examine the influence of late treatment-related toxicity on HRQOL.

Materials and methods

Conceptual model

To examine the influence of late treatment-related toxicity on HRQOL, we constructed a conceptual model (Fig. 1). In order to minimize multicollinearity in our analyses, we only included factors that are directly related to HRQOL, excluding indirect factors (i.e. variables that influence HRQOL through other variables).

HRQOL is negatively affected by radiotherapy induced xerostomia and dysphagia.^{1,2,12} Since dysphagia may be the consequence of xerostomia, these outcome measures might correlate or even interact. Next to these main variables of interest, other potentially

predictive factors were subdivided into patient related factors, disease related factors and treatment-related factors. Patient related factors include sex and age; HRQOL scores are likely to decrease with increasing age and tend to be lower for females.^{13–15} Disease related factors include tumor location and disease stage. Tumor location has a varying impact on HRQOL.^{1,2,16,17} In contrast, disease stage is unlikely to directly affect HRQOL.^{1,2,16,17} In case of a lower HRQOL for patients with advanced disease stage, the decreased HRQOL is suggested to be related to cancer treatment, treatment toxicity and/or disease progression rather than to cancer stage directly.^{2,16,18} Hence, disease stage can be considered as an indirect predictor of HRQOL and is for this reason not included in our conceptual model. Finally, with regard to treatment-related factors, the combination of radiotherapy with surgery or chemotherapy is suggested to have a negative influence on HRQOL.^{1,16} The interval after radiotherapy (follow-up period) has a varying impact on HRQOL.^{1,19}

Data collection

From June 2009 to March 2010, a multi-center cross-sectional survey was performed during planned follow-up visits in two Dutch hospitals.²⁰ The study population consisted of HNC patients, who were treated with curative intent by radiotherapy alone or combined with surgery and/or chemotherapy. Patients with a follow-up period of 6 months or longer after the start of radiotherapy and without evidence of recurrent disease were eligible for inclusion.

The EuroQol-5D questionnaire²¹ (EQ-5D) was filled out in the hospital before the patients visited their physician. During the follow-up visit, severity of xerostomia and dysphagia was scored by a trained researcher (radiation technologist) or the treating physician and converted to the RTOG scale²² (Appendix 1). The following data were retrieved from patients' medical records: date and type of initial treatment, primary tumor location and initial tumor stage. This study was approved by the Institutional Review Board.

EuroQol-5D

The EQ-5D is the most frequently used multi-attribute health status classification system and is recommended by the National Institute for Health and Clinical Excellence.^{6,21,23–25} The EQ-5D consists of questions considering five dimensions of generic HRQOL (mobility, self-care, usual activities, pain/discomfort and anxiety/depression).²¹ The answers to these questions can be combined to calculate health state preferences (so-called utility scores) from a general public perspective using a scoring function. This scoring function was based on the preferences of 2.997 UK respondents, who valued 42 different health states from the EQ-5D using the time trade-off method (TTO).²⁶ Utility scores calculated by this scoring function range from –0.59 (health state worse than death, severe problems in all five dimensions), through 0 (death) to 1 (full health, no problems in all dimensions). Next to the five questions, a visual analogue scale (VAS) is included in the EQ-5D that ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).²¹ The VAS measures the patients' self-rated HRQOL (patients' perspective).²⁷

Data analyses

Missing data

Patients with missing data for late toxicity scores were excluded from the analyses. As recommended for handling missing HRQOL data,²⁸ missing data on the EQ-5D were replaced using multiple imputation. To impute the missing values on the five questions and the VAS score of the EQ-5D, five datasets were created ($m = 5$). The imputation model included the variables




Figure 1 Conceptual model.

described in the conceptual model (Fig. 1), plus the questions and VAS of the EQ-5D. Categorical variables were imputed as scale variables and variables containing more than two categories were converted into dummy variables.^{29,30} After multiple imputation, values for the separate questions of the EQ-5D were converted back to categorical variables.²⁹

To obtain pooled estimates of the mean, variance and parametric tests the method as described by Rubin³¹ and more recently by Carlin et al.³² was used. There is no generally accepted method for pooling the (adjusted) R^2 , medians, quartiles and non-parametric tests. The (adjusted) R^2 was pooled by averaging the separate values for the (adjusted) R^2 from all five regression analyses. Medians and quartiles were pooled by obtaining the median and quartiles of all five imputed datasets combined. Non-parametric tests were pooled by averaging the test statistic for the separate tests for all five imputed datasets, which was subsequently used to calculate *p*-values.

Analyses

First, descriptive statistics were computed for the population characteristics.

Second, we examined differences in utility and VAS scores between subgroups with toxicity and without toxicity. For this purpose, patients were subdivided according to grade 0, 1, 2 and ≥ 3 for both xerostomia and dysphagia. Only subgroups with ≥ 10 patients were included in the analyses. Subsequently, skewness and kurtosis of the HRQOL distribution within these subgroups were examined. If the skewness and kurtosis fell between -2.0 and 2.0 , the differences between subgroups were compared using one way analysis of variance (ANOVA) and if significant multiple paired Student's *t*-tests were performed. Kruskal–Wallis tests and if statistically significant pairwise comparison Mann–Whitney *U* tests were performed if the skewness or kurtosis exceeded this range.

Third, to test the conceptual model presented in Fig. 1, utility and VAS scores were separately included as dependent variables in multivariate regression analyses. The variables which were considered to influence HRQOL were included in the regression model as independent variables. Grade of xerostomia and dysphagia, as well as sex, tumor location, surgery of the primary tumor and chemotherapy were included as categorical variables. Xerostomia and dysphagia were subdivided into dummy variables for grade 0 (reference category), 1, 2 and ≥ 3 . For tumor location dummy variables were created for oral cavity and lip, pharynx, larynx and other sites (reference category). Larynx and pharynx were separate categories since laryngeal carcinomas are typically early stage tumors and subsequently treated with limited radiation fields as opposed to pharynx carcinomas which are mostly locally advanced and treated with large radiation fields. Further, age and follow-up period after radiotherapy were included as scale variables. Since there is a possible interaction between xerostomia and dysphagia, effect modification (by means of an interaction term) was considered between these two variables.

Independently of the significance, none of the potentially influencing variables were excluded from the regression model. Only the interaction term between xerostomia and dysphagia was excluded if not statistically significant. The final regression models were checked for assumptions of linear regression.

All analyses were performed using SPSS 17.0. *P*-values < 0.05 were considered statistically significant.

Results

Population characteristics

Altogether, 92% of all approached patients agreed to participate. In total 426 patients filled out the questionnaire, 30 of these

patients were excluded since toxicity data were missing. This resulted in a study population of 396 patients of which 55 patients (14%) had missing values on the EQ-5D which were imputed. Population characteristics are presented in Table 1. The average utility and VAS scores among all 396 patients were 0.85 (sd: 0.18) and 75 (sd: 15), respectively.

HRQOL among patients subdivided by xerostomia and dysphagia

Subgroups were categorized by grades of xerostomia and/or dysphagia (based on the RTOG scale). In total, 84 patients (21%) had no xerostomia or dysphagia. Xerostomia was more prevalent than dysphagia (Table 2).

For the utility scores, a ceiling effect (the scores are clustered around the upper end of the scale) was observed for the subgroup without toxicity. This resulted in a distribution with a high skewness (-2.4) and kurtosis (7.2). For VAS scores, the skewness and kurtosis were within the proposed range. Therefore, subgroup

Table 1
Characteristics of the study population.^a

Patient characteristics		
Sex		
Male	276	70%
Female	120	30%
Age (years)		
Mean (Sd)	63.2	(11.8)
Minimum, maximum	20	99
Follow-up period (months)		
Median (IR)	20	(23.0)
Minimum, maximum	6	152
Disease characteristics		
Tumor location		
Oral cavity and lip	51	13%
Pharynx	115	29%
Larynx	125	32%
Nasal cavity and sinuses	20	5%
Salivary gland	23	6%
Other ^b	49	12%
Unknown	13	3%
Tumor classification		
Tis	8	2%
T0	17	4%
T1	92	23%
T2	115	29%
T3	55	14%
T4	82	21%
Unknown	27	7%
Node classification		
N0	194	49%
N1	57	14%
N2	121	31%
N3	9	2%
Unknown	15	4%
Stage (UICC)		
0	7	2%
I	55	14%
II	59	15%
III	78	20%
IV	139	35%
Unknown	58	15%
Treatment characteristics		
Surgery of the primary tumor		
No	258	65%
Yes	138	35%
Chemotherapy		
No	339	86%
Yes	57	14%

Abbreviation: Sd, standard deviation; RT, radiotherapy; IR, interquartile range.

^a Values are numbers/percentages unless stated otherwise.

^b Including skin and unknown primary tumors.

Table 2
Health-related quality of life categorized by xerostomia and dysphagia.

Utility scores ^c	Xerostomia																	
	0				1				2				3+					
	Dysphagia	Mean (Sd)	Median	(IR)	N	(N imp)	Mean (Sd)	Median	(IR)	N	(N imp)	Mean (Sd)	Median	(IR)	N	(N imp)		
0	0.909	(0.161)	1.000	(0.186)	84	(1)	0.898	(0.138)	1.000	(0.204)	92	(5)	0.846	(0.177)	0.850	(0.275)	15	(2)
1	0.841	(0.144)	0.796 ^a	(0.275)	18	(3)	0.829	(0.175)	0.814 ^a	(0.275)	68	(4)	0.817	(0.187)	0.812 ^a	(0.309)	31	(3)
2					9 ^b		0.803	(0.136)	0.796 ^a	(0.133)	14	(6)	0.763	(0.213)	0.778 ^a	(0.311)	40	(3)
3+					1 ^b					6 ^b			0.758	(0.234)	0.796 ^a	(0.363)	16	(1)
Visual Analogue Scale scores ^c																		
0	80.1	(12.4)	80.0	(20.0)	84	(1)	79.5	(14.7)	80.0	(20.0)	92	(5)	76.1	(8.9)	75.0	(10.0)	15	(2)
1	73.4	(14.4)	79.0	(10.0)	18	(3)	73.9 ^c	(16.0)	75.0	(16.5)	68	(4)	69.9 ^c	(14.6)	70.0	(20.0)	31	(3)
2					9 ^b		73.8	(22.8)	71.6	(16.0)	14	(6)	67.5 ^c	(17.1)	70.0	(20.0)	40	(3)
3+					1 ^b					6 ^b			64.8 ^c	(13.9)	65.0	(10.0)	16	(1)

Abbreviations: Sd, standard deviation; IR, interquartile range; N imp, the number of imputed cases.

^a Statistically significantly ($P < 0.05$) different utility score than patients without xerostomia and dysphagia (Mann–Whitney U test).

^b Not tested for difference between subgroups ($N < 10$).

^c Statistically significantly ($P < 0.05$) different visual analogue scale score than patients without xerostomia and dysphagia (Student's t -test).

analyses were performed using non-parametric tests for utility scores and using parametric tests for VAS scores.

Utility scores were significantly different between subgroups (Kruskal–Wallis test, $P < 0.001$). Pairwise comparisons showed significantly higher utility scores for patients without toxicity compared to patients with \geq grade 1 dysphagia independently of the grade of xerostomia. For patients with dysphagia grade 0, average utility scores ranged between 0.91 (xerostomia grade 0) and 0.85 (xerostomia grade 2). For dysphagia grade 1 this ranged between 0.84 and 0.82 and between 0.80 and 0.76 for \geq grade 2 dysphagia (Table 2 and Fig. 2).

Also VAS scores were significantly different among subgroups (ANOVA, $P < 0.001$). Pairwise comparisons showed significantly lower VAS scores if patients had \geq grade 1 for both xerostomia and dysphagia, except for the subgroup with grade 1 xerostomia and grade 2 dysphagia. For patients with dysphagia grade 0, average VAS scores ranged between 80 (xerostomia grade 0) and 76 (xerostomia grade 2). For dysphagia grade 1 this ranged between 74 and 70 and between 74 and 65 for \geq grade 2 dysphagia (Table 2 and Fig. 2).

Factors influencing HRQOL

Utility scores were significantly negatively affected by grade 2 and \geq 3 xerostomia in the multivariate regression analyses (Table 3). This was also true for dysphagia grade 1 and grade 2. Grade 1 xerostomia and \geq grade 3 dysphagia had no significant impact on utility




Figure 2 HRQOL categorized by grade of xerostomia and dysphagia^a. Only subgroups with more than 10 patients are presented, error bars indicate the 95% confidence interval of the mean and values in the bars represent the N per subgroup.

Table 3
Multivariate regression model.^a

Final model (dependent variable = utility score) $R^2 = 42\%$, ^b Adjusted $R^2 = 17\%$ ^c			
Independent variables	Beta	Se	P-value
Constant	0.836	0.057	0.000
<i>Treatment toxicity</i>			
Xerostomia ^d			
Grade 1	-0.013	0.021	0.540
Grade 2	-0.059	0.028	0.040
Grade 3+	-0.336	0.123	0.006
Dysphagia ^d			
Grade 1	-0.059	0.021	0.005
Grade 2	-0.126	0.029	0.000
Grade 3+	-0.074	0.040	0.060
<i>Patient characteristics</i>			
Sex			
Male	0.052	0.019	0.006
Age	0.000	0.001	0.747
<i>Disease characteristics</i>			
Tumor location ^d			
Oral cavity and lip	0.081	0.030	0.006
Pharynx	0.063	0.027	0.018
Larynx	0.032	0.026	0.226
<i>Treatment characteristics</i>			
Surgery of the primary tumor			
Yes	0.062	0.022	0.006
Chemotherapy			
Yes	0.040	0.027	0.148
Follow-up period	0.000	0.000	0.499
<i>Interaction</i>			
Xerostomia and Dysphagia	-	-	ns
$R^2 = 39\%$, ^b Adjusted $R^2 = 16\%$ ^c			
Constant	79.4	4.9	0.000
<i>Treatment toxicity</i>			
Xerostomia ^d			
Grade 1	-1.6	1.9	0.412
Grade 2	-7.7	2.6	0.003
Grade 3+	8.2	11.1	0.460
Dysphagia ^d			
Grade 1	-5.6	1.8	0.002
Grade 2	-7.2	3.0	0.026
Grade 3+	-10.8	3.4	0.002
<i>Patient characteristics</i>			
Sex			
Male	1.4	1.7	0.397
Age	-0.1	0.1	0.310
<i>Disease characteristics</i>			
Tumor location ^d			
Oral cavity and lip	5.9	2.7	0.031
Pharynx	4.7	2.3	0.040
Larynx	1.9	2.2	0.398
<i>Treatment characteristics</i>			
Surgery of the primary tumor			
Yes	4.0	2.0	0.043
Chemotherapy			
Yes	4.4	2.4	0.068
Follow-up period	0.0	0.0	0.757
<i>Interaction</i>			
Xerostomia and Dysphagia	-	-	ns

Abbreviations: Se, standard error; ns, not statistically significant.

^a For the complete case analyses see Appendix.

^b R^2 = the fraction of the total squared error that is explained by the regression model.³⁸

^c Adjusted R^2 = measure indicating how much variance in the outcome would be accounted for if the model had been derived from the population from which the sample was taken.³⁸

^d Reference category for dummy variables was Grade 0 toxicity and other tumor locations.

scores. Other significant influencing variables were sex, tumor location and whether surgery of the primary tumor was performed. The

interaction term for xerostomia and dysphagia was not significant and therefore excluded from the regression model.

VAS scores were significantly negatively influenced by grade 2 xerostomia in the multivariate regression analyses (Table 3). Also, all grades of dysphagia (grade 1, 2 and ≥ 3) had a significantly negative impact on VAS scores. Xerostomia grade 1 and ≥ 3 had no significant impact on VAS scores. Other statistically significant variables in the regression model were: tumor location, whether surgery of the primary tumor was performed and whether patients received chemotherapy. The interaction term for xerostomia and dysphagia was not statistically significant and therefore excluded from the regression model.

The regression models were checked for the assumptions of linear regression and no severe deficiencies were observed.

Discussion

To the best of our knowledge, this study was the first to analyze the impact of late treatment-related toxicity on patient-rated utility and VAS scores in HNC. Our analyses demonstrated that dysphagia and xerostomia both have a negative impact on HRQOL. Moreover, dysphagia had the largest impact on HRQOL. Except for age, follow-up period and whether patients received chemotherapy all independent variables reported in the conceptual model (Fig. 1) were significant predictors of HRQOL in at least one of the two regression analyses. The relations were as expected, except for surgery. The complete case analyses resulted in comparable regression models (Appendix 2).

Potential limitations of this study included the low number of patients with grade ≥ 3 toxicity (Table 2). This might explain the fact that grade ≥ 3 dysphagia was not a significant predictor of utility scores. The same may apply to grade ≥ 3 xerostomia for VAS scores. Also, the cross-sectional design and hence the inability to correct for baseline HRQOL may be considered as a limitation. However, we corrected for potentially confounding variables and to our knowledge there was no rationale to assume that the HRQOL before treatment was on average different between the subgroups subdivided by treatment toxicity. Therefore, the impact of late treatment-related toxicity on HRQOL in our study can probably not be attributed to the cross-sectional design. Nevertheless, prospective studies measuring utility and VAS scores in HNC patients with different grades of toxicity are needed to confirm our results. Finally, we included patients who had a follow-up period of at least 6 months from treatment start. This includes patients who have been studied 4–5 months following completion of radiotherapy. It is unclear whether xerostomia and dysphagia have stabilized after this period. However, additional analyses showed that if the 21 patients (5%) with a shorter follow-up than 6 months from treatment completion were excluded, the HRQOL estimates stratified by xerostomia and dysphagia remained similar.

The current study showed on average relatively higher utility than VAS scores. In contrast with our results, previous studies indicated that patients with a specific condition (patients' perspective) are inclined to place higher scores for their own health state compared with non-patients (general public perspective), presumably due to adaptation.^{33–36} However, corresponding with our results, most studies indicated that due to differences in measurement methods, utility scores based on the TTO method (as in this study) are higher than VAS scores.^{6,33} Despite these abovementioned differences between utility and VAS scores, the decrements between the subgroups subdivided by xerostomia and dysphagia were comparable between the two methods. Therefore, the differences between utility and VAS scores probably represent an overall shift in HRQOL for all subgroups and do not alter the estimated impact of xerostomia and dysphagia on HRQOL.

Previously, utility scores in HNC have been estimated using various methods.^{7–11} Based on the EQ-5D filled out by 50 oncology nurses, Brown et al. reported an average utility score of 0.86 for post-treatment HNC patients with loco-regional disease control.⁷ This corresponds with the overall average utility score of 0.85 in our study. Ringash et al. applied the TTO method in 112 disease free laryngeal cancer patients resulting in a higher utility score of 0.91.¹⁰ Due to difference in patient populations or subgroups it was not possible to compare utility scores from the other studies with our results.^{8,9,11}

Marra et al.,³⁷ defined 0.03 as a minimally important difference in utility scores (measured by the EQ-5D). Accordingly, the main clinical implications of our results are that treatment strategies aimed at reducing dysphagia and/or xerostomia have the potential to result in a meaningful improvement of generic HRQOL. This emphasizes that next to the expected length of survival also treatment toxicity should be considered when treatment choices are made. Our results can be used to inform this trade-off. In consideration of this trade-off, xerostomia is more prevalent than dysphagia, whereas dysphagia has a higher impact on HRQOL than xerostomia. Therefore, preventing xerostomia could benefit more patients, whereas preventing dysphagia might have a larger benefit per patient.

To reduce treatment toxicity, it may be useful to focus on patients who have the highest risk of experiencing xerostomia and/or dysphagia. In our study population, 84 patients (21%) had no toxicity. Compared with the 312 patients (79%) with any grade of toxicity, the patient group without toxicity consisted of less patients with advanced disease stage (III/IV: 27% versus 62%), had relatively less pharyngeal cancer patients (29% versus 43%) and more laryngeal cancer patients (36% versus 5%). Hence, patients with advanced disease stage and/or pharyngeal cancer may have a higher chance of experiencing xerostomia and/or dysphagia. However, this needs to be confirmed in prospective studies.

In conclusion, our results can be used to support clinical decision making. They underscore the importance that, next to survival data, clinical studies examine toxicity and its impact on generic HRQOL. This assists the trade-off between length and quality of survival. Our study suggests that xerostomia and dysphagia have a negative impact on HRQOL; moreover it was found that dysphagia affects patients' HRQOL stronger than xerostomia.

Conflict of interest statement

No actual or potential conflicts of interest exist.

Ethical statement

The work has been approved by the appropriate ethical committees related to the institutions in which it was performed.

Acknowledgements

Ann Claessens, Ria Debougnoux, Prof. Dr. Bernd Kremer, Dr. Kenneth Kross, Dr. Martin Lacko, Chantal Overhof and Michel Walthouwer are gratefully acknowledged for their support during the data collection.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.oraloncology.2011.05.012.

References

- Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. *J Clin Oncol* 2008;**26**(22):3770–6.
- Hammerlid E, Taft C. Health-related quality of life in long-term head and neck cancer survivors: a comparison with general population norms. *Br J Cancer* 2001;**84**(2):149–56.
- Rogers SN, Ahad SA, Murphy AP. A structured review and theme analysis of papers published on 'quality of life' in head and neck cancer: 2000–2005. *Oral Oncol* 2007;**43**(9):843–68.
- Sayed SI, Elmihyeh B, Rhys-Evans P, Syrigos KN, Nutting CM, Harrington KJ, et al. Quality of life and outcomes research in head and neck cancer: a review of the state of the discipline and likely future directions. *Cancer Treat Rev* 2009;**35**:397–402.
- Bentzen SM, Dorr W, Anscher MS, Denham JW, Hauer-Jensen M, Marks LB, et al. Normal tissue effects: reporting and analysis. *Semin Radiat Oncol* 2003;**13**(3):189–202.
- Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. *Methods for the Economic Evaluation of Health Care Programmes*. Oxford: Oxford University Press; 2005.
- Brown B, Diamantopoulos A, Bernier J, Schoffski P, Hieke K, Mantovani L, et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. *Value Health* 2008;**11**(5):791–9.
- Paleri V, Kelly CG. Re-irradiation with concurrent chemotherapy in recurrent head and neck cancer: a decision analysis model based on a systematic review. *Clin Otolaryngol* 2008;**33**(4):331–7.
- Schneider SM, Pouget I, Staccini P, Rampaal P, Hebuterne X. Quality of life in long-term home enteral nutrition patients. *Clin Nutr* 2000;**19**(1):23–8.
- Ringash J, Redelmeier DA, O'Sullivan B, Bezjak A. Quality of life and utility in irradiated laryngeal cancer patients. *Int J Radiat Oncol Biol Phys* 2000;**47**(4):875–81.
- Schwartz SR, McDowell J, Yueh B. Numeracy and the shortcomings of utility assessment in head and neck cancer patients. *Head Neck* 2004;**26**(5):401–7.
- Lovell SJ, Wong HB, Loh KS, Ngo RY, Wilson JA. Impact of dysphagia on quality-of-life in nasopharyngeal carcinoma. *Head Neck* 2005;**27**(10):864–72.
- Fryback DG, Dunham NC, Palta M, Hanmer J, Buechner J, Cherepanov D, et al. US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. *Med Care* 2007;**45**(12):1162–70.
- Hanmer J, Hays RD, Fryback DG. Mode of administration is important in US national estimates of health-related quality of life. *Med Care* 2007;**45**(12):1171–9.
- Kind P, Hardman G, Macran S. UK population norms for EQ-5D. 1999; <http://ideas.repec.org/p/chy/respap/172chedp.html>.
- Terrell JE, Ronis DL, Fowler KE, Bradford CR, Chepeha DB, Prince ME, et al. Clinical predictors of quality of life in patients with head and neck cancer. *Arch Otolaryngol Head Neck Surg* 2004;**130**(4):401–8.
- Fang FM, Tsai WL, Chien CY, Chiu HC, Wang CJ, Chen HC, et al. Changing quality of life in patients with advanced head and neck cancer after primary radiotherapy or chemoradiation. *Oncology* 2005;**68**(4–6):405–13.
- Allison PJ, Locker D, Wood-Dauphinee S, Black M, Feine JS. Correlates of health-related quality of life in upper aerodigestive tract cancer patients. *Qual Life Res* 1998;**7**(8):713–22.
- Jellema AP, Slotman BJ, Doornaert P, Leemans CR, Langendijk JA. Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer. *Int J Radiat Oncol Biol Phys* 2007;**69**(3):751–60.
- ClinicalTrials.gov. Quality of Life in Patients Treated for Head and Neck Cancer (NCT00963586). 2009; <http://clinicaltrials.gov/ct2/show/NCT00963586>.
- EuroQol Group. EuroQol – A new facility for the measurement of health-related quality of life. The EuroQol Group. *Health Policy* 1990;**16**(3):199–208.
- Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). *Int J Radiat Oncol Biol Phys* 1995;**31**(5):1341–6.
- Brauer CA, Rosen AB, Greenberg D, Neumann PJ. Trends in the measurement of health utilities in published cost-utility analyses. *Value Health* 2006;**9**(4):213–8.
- Rasanen P, Roine E, Sintonen H, Semberg-Konttinen V, Ryyanen OP, Roine R. Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review. *Int J Technol Assess Health Care* 2006;**22**(2):235–41.
- National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. 2008; <http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf>.
- Dolan P. Modeling valuations for EuroQol health states. *Med Care* 1997;**35**(11):1095–108.
- Cheung K. Y., Oemar M., Oppe M. and Rabin R. User Guide: Basic information on how to use EQ-5D. 2010; http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Office/User_Guide_v3_April_2010_.pdf.
- Fielding S, Fayers P, Ramsay C. Predicting missing quality of life data that were later recovered: an empirical comparison of approaches. *Clin Trials* 2010;**7**(4):333–42.
- Allison PD. Missing Data. Thousand Oaks: Sage; 2002.
- Graham JW. Missing data analysis: making it work in the real world. *Annu Rev Psychol* 2009;**60**:549–76.
- Rubin DB. *Multiple imputation for nonresponse in surveys*. New York: John Wiley; 1987.

32. Carlin JB, Li N, Greenwood P, Coffey C. Tools for analyzing multiple imputed datasets. *Stata Journal* 2003;**3**(3):226–44.
33. Brauer CA, Neumann PJ. Quality-adjusted life years: how useful in medico economic studies. *Fundam Clin Pharmacol* 2005;**19**(6):603–7.
34. Dolan P. Valuing health-related quality of life. Issues and controversies. *Pharmacoeconomics* 1999;**15**(2):119–27.
35. Dolan P. Whose preferences count? *Med Decis Making* 1999;**19**(4):482–6.
36. Rashidi AA, Anis AH, Marra CA. Do visual analogue scale (VAS) derived standard gamble (SG) utilities agree with Health Utilities Index utilities? A comparison of patient and community preferences for health status in rheumatoid arthritis patients. *Health Qual Life Outcomes* 2006;**4**(25).
37. Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. *Soc Sci Med* 2005;**60**(7):1571–82.
38. Field A. *Discovering statistics using SPSS*. 2nd ed. Sage Publications Ltd.; 2005.